FLII and Ewing sarcoma: The resulting chimeric fusion protein, EWS/FLI, is pathognomonic to Ewing sarcoma, and acts as a powerful chromatin regulator and aberrant transcription factor by activating oncogenes and reshaping the epigenetic landscape to cause tumorigenesis through activity at Ewing-specific GGAA repeat response elements (59).